OSE Immunotherapeutics — New UC biomarker underpins growth strategy
OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and...
239 Views
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
248 Views
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
228 Views
OSE Immunotherapeutics — Strategic collaboration in mRNA technologies
OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop...
249 Views
OSE Immunotherapeutics — Lusvertikimab impresses in extension period data
OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of...
230 Views